Oral vancomycin    (DrugBank: Vancomycin)

2 diseases
IDDisease name (Link within this page)Number of trials
94Primary sclerosing cholangitis4
296Biliary atresia1

94. Primary sclerosing cholangitis    [ 134 clinical trials,   105 drugs,   (DrugBank: 37 drugs),   18 drug target genes,   131 drug target pathways]
Searched query = "Primary sclerosing cholangitis", "PSC"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
4 / 134 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03046901
(ClinicalTrials.gov)
December 7, 201631/1/2017Vancomycin Treatment in Recurrent PSC in Liver Transplant PatientsOral Vancomycin Treatment in Recurrent Primary Sclerosing Cholangitis in Liver Transplant RecipientsPrimary Sclerosing Cholangitis;Post- Orthotopic Liver TransplantationDrug: VancomycinOchsner Health SystemNULLWithdrawnN/AN/AAll0N/AUnited States
2NCT02605213
(ClinicalTrials.gov)
September 201531/10/2015Effect and Safety of Oral Vancomycin in Primary Sclerosing Cholangitis PatientsEvaluation of Effectiveness and Safety of Oral Vancomycin in Treatment of Primary Sclerosing Cholangitis.Primary Sclerosing CholangitisDrug: Vancomycin;Drug: PlaceboTehran University of Medical SciencesNULLRecruiting18 Years60 YearsBoth30Phase 4Iran, Islamic Republic of
3NCT01802073
(ClinicalTrials.gov)
January 201221/2/2013Primary Sclerosing Cholangitis With Oral Vancomycin by the Study of Its Antimicrobial and Immunomodulating EffectsTreatment of Primary Sclerosing Cholangitis in Inflammatory Bowel Disease Patients With Oral Vancomycin by the Study of Its Antimicrobial and Immunomodulating EffectsPrimary Sclerosing CholangitisDrug: Oral VancomycinStanford UniversityNULLCompleted1 YearN/AAll34Phase 3United States
4NCT02137668
(ClinicalTrials.gov)
July 201012/5/2014Treating Primary Sclerosing Cholangitis and Biliary Atresia With VancomycinThe Human Gastrointestinal Tract Microbiota in the Setting of Treating Primary Sclerosing Cholangitis and Biliary Atresia With VancomycinPrimary Sclerosing Cholangitis;Biliary AtresiaDrug: Oral VancomycinSacramento Pediatric GastroenterologyNULLRecruitingN/A40 YearsBoth200Phase 1United States

296. Biliary atresia    [ 53 clinical trials,   56 drugs,   (DrugBank: 31 drugs),   43 drug target genes,   50 drug target pathways]
Searched query = "Biliary atresia"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 53 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02137668
(ClinicalTrials.gov)
July 201012/5/2014Treating Primary Sclerosing Cholangitis and Biliary Atresia With VancomycinThe Human Gastrointestinal Tract Microbiota in the Setting of Treating Primary Sclerosing Cholangitis and Biliary Atresia With VancomycinPrimary Sclerosing Cholangitis;Biliary AtresiaDrug: Oral VancomycinSacramento Pediatric GastroenterologyNULLRecruitingN/A40 YearsBoth200Phase 1United States